newsfilter
← Latest News
GlobeNewswire·

NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Company has initiated pre-IND discussions with the FDA for its first AIM INJ indicationNEXI-001 completed enrollment in its final safety cohorts and all patients have been dosed; Company continues to follow patients and